American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth…

By C. Allegra, J. Jessup, M. Somerfield, S. Hamilton, E. Hammond, D. Hayes, Pamela K. McAllister, R. Morton, R. Schilsky. Journal of Clinical Oncology, 2009

1,180 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/aa0a9f1f9632f80628754fb55790e9de1f2e4ad8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Trey Ideker
2. A. Bardelli
3. Hannah Carter

In Oncology

1. Trey Ideker

Citations in the corpus

• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, background): “RECENT RETROSPECTIVE CORrelative analyses of metastatic colorectal cancer trials indicate that patients with KRAS-mutated tumors (NCBI Entrez Gene 3845) do not benefit from the anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab and panitumumab.(1) These retrospective analys”
• Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. (2012, background): “The ability to direct targeted cancer agents based on tumorspecific molecular abnormalities has had a clear and positive impact on the management of patients with non-small cell lung, breast, colon, skin, and gastrointestinal tumors [3–7].”
• Network-based stratification of tumor mutations (2013, background): “Although individual mutations in cancer genes have long been used to stratify patients 14–17 , stratification based on the entire mutation profile has been more challenging.”